Research programme: anticancer and antiviral immunotherapeutics - AvidBioticsAlternative Names: MICA-fusion proteins; Micacide™ proteins
Latest Information Update: 16 Sep 2013
At a glance
- Originator AvidBiotics Corp.
- Class Immunoproteins; Recombinant fusion proteins
- Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Viral infections
Most Recent Events
- 10 Sep 2013 Preclinical trials in Viral infections in USA (Parenteral)
- 10 Sep 2013 Preclinical trials in Cancer in USA (Parenteral)